The Society for Immunotherapy of Cancer (SITC) Annual Meeting & Pre-Conference Programs brings together stakeholders across the cancer immunotherapy field to advance the science, discover breakthroughs and educate the world on cancer immunotherapy.
As the largest conference solely focused on cancer immunotherapy, the Annual Meeting & Pre-Conference Programs provides more than 2,700 international leaders from academia, regulatory and government agencies, as well as industry representatives with a multidisciplinary educational and interactive environment focused on improving outcomes for all cancer patients.
Registration is currently open for the 32nd Annual Meeting & Pre-Conference Programs!
Scheduled for November 8-12 in National Harbor, Md., the event will take place at the Gaylord National Hotel & Convention Center. Register today to join us at the premier destination for scientific exchange, education and networking in the cancer immunotherapy field!
Click on the titles below to view each program's schedule, purpose, educational objectives and world-renowned faculty.
Concurrent Program I: Primer on Tumor Immunology and Cancer Immunotherapy™
Concurrent Program II: Workshop on Single Cell Techniques in Immunology and Cancer Immunotherapy 8 a.m. – 5 p.m.
Looking for archived SITC Annual Meeting content? Visit past conference websites below:
The following are future scheduled dates and locations for the society's Annual Meeting & Pre-Conference Programs:
Nov. 7-11, 2018 at the Walter E. Washington Convention Center
Nov. 6-10, 2019 at the Gaylord National Hotel & Convention Center
National Harbor, Maryland
Nov. 11-15, 2020 at the Gaylord National Hotel & Convention Center
National Harbor, Maryland
Nov. 10-14, 2021 at the Walter E. Washington Convention Center
Learn from past delegates why you cannot miss the SITC Annual Meeting & Pre-Conference Programs in the following videos:
Therapy-related myeloid neoplasms (WHO classification) with mutated TP53 or complex chromosome aberrations are not likely to be cured with targeted agents. These neoplasms comprise a group of clonal hematopoietic stem cell disorders related to prior ...
The Department of Immunology, Genetics and Pathology (IGP) at Uppsala University in Sweden is involved in an ongoing effort to collect cancer patient data in an initiative entitled U-CAN. By June of this year, the biobank has grown to approximately ...
It is the recent modest single agent activity of programmed death-ligand 1 and programmed death receptor-1 antibodies for those with breast cancer that is generating hope for use of immunotherapy in breast cancer. To ponder in the meantime, in preparation ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org